Long-term follow-up in atrophic body gastritis patients

Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection

E. Lahner, C. Bordi, M. S. Cattaruzza, C. Iannoni, M. Milione, G. Delle Fave, B. Annibale

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8%) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88%) of the eight patients with neoplastic lesions, but only in 15 (15%) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.

Original languageEnglish
Pages (from-to)471-481
Number of pages11
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number5
DOIs
Publication statusPublished - Sep 1 2005

Fingerprint

Atrophic Gastritis
Metaplasia
Helicobacter Infections
Helicobacter pylori
Atrophy
Serology
Histology
Gastroscopy
Gastritis
Adenoma
Adenocarcinoma
Biopsy
Antral

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Long-term follow-up in atrophic body gastritis patients : Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. / Lahner, E.; Bordi, C.; Cattaruzza, M. S.; Iannoni, C.; Milione, M.; Delle Fave, G.; Annibale, B.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 5, 01.09.2005, p. 471-481.

Research output: Contribution to journalArticle

@article{fb54c90b56de4890917f595055473d09,
title = "Long-term follow-up in atrophic body gastritis patients: Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection",
abstract = "Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8{\%}) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88{\%}) of the eight patients with neoplastic lesions, but only in 15 (15{\%}) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.",
author = "E. Lahner and C. Bordi and Cattaruzza, {M. S.} and C. Iannoni and M. Milione and {Delle Fave}, G. and B. Annibale",
year = "2005",
month = "9",
day = "1",
doi = "10.1111/j.1365-2036.2005.02582.x",
language = "English",
volume = "22",
pages = "471--481",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Long-term follow-up in atrophic body gastritis patients

T2 - Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection

AU - Lahner, E.

AU - Bordi, C.

AU - Cattaruzza, M. S.

AU - Iannoni, C.

AU - Milione, M.

AU - Delle Fave, G.

AU - Annibale, B.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8%) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88%) of the eight patients with neoplastic lesions, but only in 15 (15%) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.

AB - Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8%) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88%) of the eight patients with neoplastic lesions, but only in 15 (15%) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.

UR - http://www.scopus.com/inward/record.url?scp=24344488684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344488684&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02582.x

DO - 10.1111/j.1365-2036.2005.02582.x

M3 - Article

VL - 22

SP - 471

EP - 481

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -